Skip to main content

Market Overview

UPDATE: Ascendiant Capital Markets Downgrades PhotoMedex Following Completion Of LCA Vision Acquisition

Share:

In a report published Thursday, Ascendiant Capital Markets analyst Keay Nakae downgraded the rating on PhotoMedex (NASDAQ: PHMD) from Buy to Hold, and removed the $18.00 price target.

In the report, Ascendiant Capital Markets noted, “The acquisition of LCA Vision has now been completed. The objective of this acquisition is to leverage LCA's 62 existing stand-alone LasikPlus centers, to perform Xtrac procedures. The Company will fund this $106.5 MM transaction through a new $85 MM senior secured credit facility ($75 MM to fund the acquisition and a $10 MM line of credit) and about $3 MM in net cash.”

PhotoMedex closed on Wednesday at $12.27.

Latest Ratings for PHMD

DateFirmActionFromTo
Nov 2014Canaccord GenuityMaintainsHold
Aug 2014Canaccord GenuityDowngradesBuyHold
May 2014Ascendiant CapitalDowngradesBuyHold

View More Analyst Ratings for PHMD

View the Latest Analyst Ratings

 

Related Articles (PHMD)

View Comments and Join the Discussion!

Posted-In: Ascendiant Capital Markets Keay NakaeAnalyst Color Downgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com